Roy Eldor

Roy Eldor

Auto-generated profile, based on publicly available information

Roy Eldor

Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Institute of Endocrinology, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2011 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
RERoy Eldor
Roy Eldor
BGBenjamin Glaser
Benjamin Glaser
MFMerav Fraenkel
Merav Fraenkel
VDVictoria Doviner
Victoria Doviner
ASAsher Salmon
Asher Salmon
DGDavid J. Gross
David J. Gross

9 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RERoy Eldor
Roy Eldor
EAEhud Arbit
Ehud Arbit
ACAsher Corcos
Asher Corcos
MKMiriam Kidron
Miriam Kidron
The unpredictable behavior of uncontrolled type 1 diabetes often involves frequent swings in blood glucose levels that impact maintenance of a daily routine. An intensified insulin regimen is often unsuccessful, while other therapeutic options, such as amylin analog injections, use of continuous glucose sensors, and islet or pancreas transplantation are of limited clinical use. In efforts to provide patients with a more compliable treatment method, Oramed Pharmaceuticals tested the capacity of its oral insulin capsule (ORMD-0801, 8 mg insulin) in addressing this resistant clinical state. Eight Type I diabetes patients with uncontrolled diabetes (HbA1c: 7.5–10%) were monitored throughout the 15-day study period by means of a blind continuous glucose monitoring device. Baseline patient blood glucose behavior was monitored and recorded over a five-day pretreatment screening period. During the ensuing ten-day treatment phase, patients were asked to conduct themselves as usual and to self-administer an oral insulin capsule three times daily, just prior to meal intake. CGM data sufficient for pharmacodynamics analyses were obtained from 6 of the 8 subjects. Treatment with ORMD-0801 was associated with a significant 24.4% reduction in the frequencies of glucose readings >200 mg/dL (60.1±7.9% pretreatment vs. 45.4±4.9% during ORMD-0801 treatment; p = 0.023) and a significant mean 16.6% decrease in glucose area under the curve (AUC) (66055±5547 mg/dL/24 hours vs. 55060±3068 mg/dL/24 hours, p = 0.023), with a greater decrease during the early evening hours. In conclusion, ORMD-0801 oral insulin capsules in conjunction with subcutaneous insulin injections, well tolerated and effectively reduced glycemia throughout the day. Trial Registration Clinicaltrials.gov NCT00867594 .

1 November 2009 in Diabetes Care
Verified
Journal Article
Open access
RERoy Eldor
Roy Eldor
IRItamar Raz
Itamar Raz

21 November 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
RERoy Eldor
Roy Eldor
BFBruce H. Francis
Bruce H. Francis
AFAlexander Fleming
Alexander Fleming
JNJoel Neutel
Joel Neutel
KHKenneth Homer
Kenneth Homer
JRJulio Rosenstock
Julio Rosenstock

26 July 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
RERoy Eldor
Roy Eldor
JNJoel Neutel
Joel Neutel
KHKenneth Homer
Kenneth Homer
MKMiriam Kidron
Miriam Kidron

17 July 2025 in Diabetes Care
Verified
Journal Article
Closed access
RERoy Eldor
Roy Eldor
NANoa Avraham
Noa Avraham
OROrit Rosenberg
Orit Rosenberg
MSMiriam Shpigelman
Miriam Shpigelman
AGAvivit Golan-Cohen
Avivit Golan-Cohen
ABAssaf Buch
Assaf Buch
OBJECTIVE: To determine whether a slower, flexible titration regimen of semaglutide would improve adherence and reduce gastrointestinal adverse events (GI-AEs) compared with the label-recommended regimen in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 104 patients with T2D were randomized to label-recommended titration (0.25 mg, 0.5 mg, 1 mg at 4-week intervals) or flexible titration (starting at 0.0675 mg [measured as five clicks made by the dose selector dial], with gradual increases by 0.0675 mg/week and delays for GI-AEs) for 26 weeks. RESULTS: While final doses were similar between groups, only 2% of patients in the flexible arm withdrew due to GI-AEs vs. 19% in the label arm (P = 0.005). The flexible arm reported less nausea (45.1% vs. 64.2%; P = 0.051) and asthenia (9.8% vs. 24.5%; P = 0.047), with fewer days experiencing nausea (2.88 vs. 6.3 days; P = 0.017). HbA1c and BMI changes were similar between groups. CONCLUSIONS: Slower, flexible titration improved adherence and reduced adverse events without compromising efficacy.